New pill for high cholesterol shows promise in early trial

NCT ID NCT04079530

Completed Disease control Sponsor: Kowa Company, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a new controlled-release version of the drug pemafibrate in 60 adults with dyslipidemia (abnormal levels of fats in the blood). The goal was to see if the new version works as well or better than the current immediate-release tablet, with fewer side effects. Participants received different doses of the drug over two periods, and researchers measured changes in triglycerides and cholesterol levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pemafibrate (a drug to lower blood fats)
What this could lead to: If successful, this could lead to a more convenient, once-daily pill for managing high triglycerides and cholesterol.
What could go wrong: This is an early Phase 2 study with only 60 participants, so results may not apply to everyone. The new controlled-release form might not work better or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias hyperlipidemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIAS

Contacts and locations

Locations

Medical Corporation Heishinkai OPHAC Hospital

Osaka, 532-0003, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.